25 July 2025
25 July 2025
The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including Switzerland and Canada.
Positive topline results of the LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.
SSGJ-707 is a bispecific antibody that targets PD-1 and VEGF and was developed using 3SBio’s CLF2 platform.
The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation.
Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.
Daratumumab is co-formulated with Halozyme's Enhanze technology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
